2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00231140 (ClinicalTrials.gov)	December 2005	30/9/2005	Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)	Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS)	Drug: Thalidomide (drug)	Charite University, Berlin, Germany	NULL	Terminated	25 Years	80 Years	Both	40	Phase 2	Germany
2	NCT00140452 (ClinicalTrials.gov)	February 2005	31/8/2005	Phase II Study Using Thalidomide for the Treatment of ALS	Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis;ALS	Drug: Thalidomide	Dartmouth-Hitchcock Medical Center	Celgene Corporation	Completed	18 Years	80 Years	Both	24	Phase 2	United States